Abstract: Provided are a small interfering RNA (siRNA) molecule which inhibits the expression of the PCSK9 gene and a pharmaceutical composition thereof, as well as a method for reducing the expression level of the PCSK9 gene by using the siRNA molecule or the pharmaceutical composition thereof. The siRNA molecules may be used to treat and/or prevent PCSK9 gene-mediated diseases.

Abstract: Disclosed are a new-type nucleic acid unit for construction of a polymeric nucleic acid and the polymeric nucleic acid for interfering with target gene expression. In the present application, by design and construction of the new-type nucleic acid unit and the self-assembled polymeric nucleic acid thereof, multiple target interference may be realized, wherein the same may be used for inhibiting multiple gene expressions in a signaling pathway of disease occurrence or development, or simultaneously inhibiting multiple disease target genes expression, possessing broad application prospects in multiple subject fields such as biology and chemistry. The polymeric nucleic acid may target multiple sequences simultaneously, wherein the sequences may be located in one or more genes.

Abstract: Provided are siRNAs or chemically-modified siRNAs targeted against ADAMTS-5 or ADAM17 for inhibiting the expression of ADAMTS-5 or ADAM17. Use of the siRNAs for treating an ADAMTS-5 or ADAM17 associated disease, such as arthritis and other inflammation-related diseases, by injecting the siRNAs or preparations comprising the siRNAs into an articular cavity of the patient, are also provided.

Abstract: Provided are siRNAs or chemically-modified siRNAs targeted against ADAMTS-5 or ADAM17 for inhibiting the expression of ADAMTS-5 or ADAM17. Use of the siRNAs for treating an ADAMTS-5 or ADAM17 associated disease, such as arthritis and other inflammation-related diseases, by injecting the siRNAs or preparations comprising the siRNAs into an articular cavity of the patient, are also provided.